WeVote
Log In

Bill

Bill

SB 1140

Relating to establishment of the Texas Rare Disease Advisory Council.

89th Legislature (2025) Introduced by Borris Miles

Texas bill establishes Rare Disease Advisory Council to coordinate state policy and services for patients with rare diseases.

Referred to Health & Human Services
#education--higher--healthinstitutions(i0237) #health&humanservicescommission(v0177) #health--otherdiseases&medicalconditions(i0383) #insurance #commissionerof(v0396) #rarediseaseadvisorycouncil #texas(v1220) #statehealthservices #departmentof(v0463) #stateagencies #boards&commissions--newlyproposed(i0773)
0
WeVote Research Nonpartisan
Bill Summary · SB 1140

Legislative bill overview

SB 1140 establishes the Texas Rare Disease Advisory Council, a new state advisory body dedicated to addressing issues related to rare diseases. The council would provide recommendations and guidance on policy matters affecting patients with rare diseases and coordinate efforts across state agencies and stakeholders.

Why is this important

Rare diseases affect millions of Americans but often receive limited research funding and policy attention due to small individual patient populations. Creating a dedicated advisory council could improve coordination of care, increase awareness among healthcare providers, and help shape state policies that better serve this underserved population.

Potential points of contention

  • Funding and staffing: The bill's fiscal impact remains unclear; establishing and maintaining a new advisory council requires resources that could be allocated elsewhere
  • Advisory vs. regulatory power: Councils typically lack enforcement authority, raising questions about whether recommendations will translate into meaningful policy changes
  • Scope and membership: The composition of the council and which rare diseases receive priority attention could become contentious among patient advocacy groups

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.